

OVERVIEW OF DEPARTMENT STAFF MEMBERS INVOLVEMENT IN PROJECT IMPLEMENTATION

Projects implemented by department staff members:

RNDr. Terézia Hudáková, PhD.

RNDr. Lucia Klimčáková, PhD.

RNDr. Helena Mičková, PhD.

RNDr. Jana Neupauerová, PhD.

RNDr. Eva Slabá, PhD.

doc. RNDr. Peter Solár, PhD.

prof. RNDr. Ján Šalagovič, PhD.

RNDr. Martina Šemeláková, PhD.

prof. RNDr. Janka Vašková, PhD.

RNDr. Jozef Židzik, PhD.

RNDr. Terézia Hudáková, PhD.

Co-investigator of projects:

- KEGA 024UPJŠ-4/2024: Implementation of practical courses in biomedical research for doctoral students and integration of researchers into new teaching approaches 'PraktikMed'
- VEGA 1/0500/23: Erythropoietin receptor and its role in cancer cell signaling
- VEGA 1/0536/19: The role of the erythropoietin receptor in the response of mammary gland adenocarcinoma to paclitaxel under In vitro and In vivo conditions
- MZ SR 2019/29-UPJŠ-1: Monitoring the relationship between selected gene variants and proteomic markers in patients with mental disorders as a contribution to their personalized treatment
- VEGA 1/0312/14: The role of candidate locus polymorphisms in the pathogenesis of non-syndromic orofacial clefts in the Slovak population
- VEGA 1/1132/12: Identification of biomarkers related to therapy effectiveness and prognosis in patients with follicular lymphoma

Bilateral mobility projects:

- FBR-PDI-012 EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic "Genomic instability and cancer "GenICa" – *co-investigator*

RNDr. Lucia Klimčáková, PhD.

Co-investigator of projects:

- VEGA 1/0050/24: Analysis of selected genetic variants associated with the efficacy of GLP-1 receptor agonists in lowering HbA1c and body weight in type 2 diabetes patients
- KEGA 024UPJŠ-4/2024: Implementation of practical courses in biomedical research for doctoral students and integration of researchers into new teaching approaches 'PraktikMed'
- VEGA 1/0534/23: Targeted genetic screening in patients with Alport syndrome–*Deputy principal investigator*
- VEGA 1/0183/20: Monitoring genomic and proteomic markers of atherosclerosis progression in peripheral and carotid arteries in type 2 diabetes
- MZ 2019/29-UPJŠ-1: Monitoring the relationship between selected gene variants and proteomic markers in patients with mental disorders as a contribution to their personalized treatment
- VEGA 1/0027/16: Monitoring associations of selected gene variants with response to treatment with oral antidiabetic drugs gliptins
- APVV-16-0158: Obesity, sleep apnea and obesity-hypoventilation syndrome: the impact of hypoxia on cardiovascular parameters in obesity-associated respiratory diseases and possibilities for therapeutic intervention

VEGA 1/0724/15:	Newly discovered genetic mutations in the etiopathogenesis of dystonias: their significance, prevalence, and manifestation
VEGA 1/0312/14:	The role of candidate locus polymorphisms in the pathogenesis of non-syndromic orofacial clefts in the Slovak population
SEPO-II:	Building infrastructure in the center of excellence, ITMS 26220120039 (2010-2013)
CEVA II:	Centrum excelentnosti pre výskum aterosklerózy, ITMS 26220120040 (2010-2013)
VEGA 1/0389/14:	Investigation of the relationship between variants of selected candidate genes for atherosclerosis and the severity of peripheral arterial occlusive disease of the lower limbs in patients with type 2 diabetes
VEGA 1/1132/12:	Identification of biomarkers related to therapy effectiveness and prognosis in patients with follicular lymphoma – <i>Deputy principal investigator</i>
VEGA 1/0340/12:	Monitoring the effect of gene polymorphisms influencing the pharmacokinetics and pharmacodynamics of metformin on the treatment response to metformin in patients with type 2 diabetes
APVV- 0134-11:	The role of hypoxia in the activation of molecular pathways associated with increased cardiovascular risk in patients with sleep apnea and their modulation by treatment.
VEGA 1/0112/11:	Investigation of the relationship between polymorphisms of selected candidate genes for atherosclerosis and the angiographically diagnosed severity of coronary artery disease in diabetic and non-diabetic patients
VEGA 1/0715/11:	Molecular genetic diagnostics in children with nephrotic syndrome
VEGA 1/0380/10:	Monitoring the impact of candidate gene polymorphisms for type 2 diabetes mellitus on the effectiveness of treatment with oral antidiabetic drugs from the sulfonylurea derivatives and dipeptidyl peptidase-4 (DPP-4) inhibitor groups
VEGA 1/0525/10:	The role of folate metabolism disorders in the pathogenesis of multiple congenital malformations
VEGA 1/0368/10:	Investigation of the impact of the genetic background of patients with chronic hepatitis C on the success of interferon therapy
VEGA 1/0864/08:	Risk of follicular lymphoma development in relation to polymorphisms in DNA repair genes
VEGA 1/4304/07:	Investigation of the effect of candidate gene polymorphisms on the age of onset of type 2 diabetes mellitus, levels of atherosclerosis risk factors, and the occurrence of macrovascular complications of diabetes
VEGA 1/3362/06:	Polymorphisms of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and folate deficiency in the Slovak population – prevalence and role in the etiopathogenesis of multifactorial diseases.

Bilateral mobility projects:

FBR-PDI-012	EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic “Genomic instability and cancer “GenICa” – <i>co-investigator</i>
-------------	---

RNDr. Helena Mičková, PhD.

Co-investigator of projects:

KEGA 024UPJŠ-4/2024: Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches 'PraktikMed'

RNDr. Jana Neupauerová, PhD.

Principal investigator:

GA UK 438 216: Identification of causal de novo variants using whole-exome and whole-genome sequencing in patients with severe epilepsy and epileptic encephalopathy

Co-investigator of projects:

IPL č. 5/2012: Elucidation of the molecular causes of hereditary neuropathies (CMT) and early non-syndromic hearing loss in children and adults using advanced sequencing, genotyping technologies, and linkage analyses

IGA MZ ČR č. NT/14348-3: Application of novel sequencing and genotyping methods in DNA analysis for effective diagnosis of rare and newly identified types of hereditary Charcot-Marie-Tooth neuropathy

AZV 15-33041A: Application of massively parallel sequencing of a gene panel associated with childhood epilepsy and epileptic encephalopathy for diagnosing the causes of epilepsy in the Czech Republic

AZV 16-30206A: Whole-genome and massively parallel RNA sequencing as a tool for elucidating the causes of rare types of hereditary neuropathies

RNDr. Eva Slabá, PhD.

Co-investigator of projects:

VEGA 1/0403/25 Analysis of biomaterials in bioprinting of mesenchymal stem cell spheroids used in tissue bioengineering

KEGA 024UPJŠ-4/202: Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches 'PraktikMed'

VEGA 1/0609/24: Identification of clinical, genetic, and biochemical markers of the onset and progression of hypersensitive pneumonitis

VEGA 1/0500/23: Erythropoietin receptor and its role in cancer cell signaling

VVGS-2016-274:	Advanced molecular-biological characterization of the probiotic strain <i>Lactobacillus plantarum</i> LS/07 CCM7766 with anti-inflammatory and anti-cancer effects (PCOV)
VEGA 1/0863/15:	Interaction of genetic background and chronic intermittent hypoxia in the pathogenesis of cardiovascular complications of obstructive sleep apnea.
VEGA 1/0389/14:	Investigation of the relationship between variants of selected candidate genes for atherosclerosis and the severity of peripheral arterial occlusive disease of the lower limbs in patients with type 2 diabetes
VEGA 1/1132/12:	Identification of biomarkers in relation to therapy effectiveness and prognosis in patients with follicular lymphoma
VEGA 1/0111/12:	Relationship between chronic intermittent hypoxia and endothelial function, as well as activation of inflammatory signaling pathways in adipose tissue in patients with sleep apnea
VEGA 1/0479/10:	Gene polymorphisms in patients with vasovagal syncope
VEGA 1/0380/10:	Monitoring the impact of candidate gene polymorphisms for type 2 diabetes mellitus on the effectiveness of treatment with oral antidiabetic drugs from the sulfonylurea derivatives and dipeptidyl peptidase-4 (DPP-4) inhibitor groups
VEGA 1/4231/07:	Association between candidate gene polymorphisms and the risk, progression, and severity of chronic obstructive pulmonary disease
VVGS 35/2006:	The effect of candidate gene polymorphisms on the onset, progression, and pharmacotherapy of chronic obstructive pulmonary disease (COPD)
VEGA 1/2312/05:	Molecular biology of pulmonary hypertension and obstructive ventilatory disorder in patients with chronic obstructive pulmonary disease
VEGA 1/0517/03:	Relationship between gene polymorphisms and pulmonary function in patients with chronic obstructive pulmonary disease

Bilateral mobility projects:

FBR-PDI-012	EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic “Genomic instability and cancer “GenICa”– <i>co-investigator</i>
-------------	--

doc. RNDr. Peter Solár, PhD.

Principal investigator:

APVV-20-012104:	Erythropoietin and its effect on tumor growth in vitro and in vivo
VEGA 1/0500/23:	Erythropoietin receptor and its role in cancer cell signaling
KEGA 024UPJŠ-4/202:	Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches ‘PraktikMed’

- VEGA 1/0536/19: The Role of the Erythropoietin receptor in the response of mammary gland adenocarcinoma to paclitaxel under In vitro and In vivo conditions
- VEGA 1/0394/15: Erythropoietin receptor in breast adenocarcinoma and its role in tamoxifen resistance
- VEGA 1/0733/12: Typing of the human erythropoietin receptor in tumor and normal cells
- VEGA 1/0296/09: Erythropoietin and its role in the angiogenesis of ovarian adenocarcinoma cells
- VEGA 1/3253/06: Molecular biological basis of the adverse effect of erythropoietin in tumor cell therapy

Project manager:

- COST - CA22119: Haemoglobinopathies in European Liaison of Medicine and Science (HELIOS) - *Project Manager for the Slovak Republic*
Hypericin: biotechnológia, signalóm, fotodynamická terapia
- Projekt ŠF EU: Innovation of the technological process for the preparation of the ITMS: 26220220157 immunomodulatory product Transfer Factor, verification of its efficacy, safety, and composition. Code: OPVaV-2001/2.2/07-SORO (2009 – 2015) - *Project Manager for UPJŠ*

Co-investigator of projects:

- APVV-0040-10: Hypericin: biotechnology, signalome, photodynamic therapy
- VEGA 1/2329/05: The role of lipid mediators in hypericin-modulated proliferation and apoptosis of tumor cells – *Deputy principal investigator*
- VEGA 1/9211/02: Hypericin in photodynamic therapy: the role of unsaturated fatty acids and their metabolites in tumor cell proliferation and differentiation – *Deputy principal investigator*
- APVV-20-003004: Study of toxicity and tolerance to heavy metals in lichen photobionts – *Deputy principal investigator*

prof. RNDr. Ján Šalagovič, PhD.

Principal investigator:

- VEGA 1/0312/14: The role of candidate locus polymorphisms in the pathogenesis of non-syndromic orofacial clefts in the Slovak population
- VEGA 1/0864/08: Risk of follicular lymphoma development in relation to polymorphisms in DNA repair genes
- VEGA 1/0517/03: Relationship between gene polymorphisms and pulmonary function in patients with chronic obstructive pulmonary disease
- VEGA 1/6040/99-02: Genetic polymorphism of phase II xenobiotic-metabolizing enzymes as a susceptibility factor in tumor development
- IG-2 LF UPJŠ: Molecular epidemiology of lung cancers (1999-2001)

Co-investigator of projects:

KEGA 024UPJŠ-4/2024:	Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches 'PraktikMed'
VEGA 1/0500/23:	Erythropoietin receptor and its role in cancer cell signaling
APVV-16-0158:	Obesity, sleep apnea and obesity-hypoventilation syndrome: the impact of hypoxia on cardiovascular parameters in obesity-associated respiratory diseases and possibilities for therapeutic intervention
CEX: EXTASY:	Excellent research team for atherosclerosis – studying the impact of hypoxia on metabolic processes from the cellular level, through tissues and organs, to the level of the patient's organism
CEVA II:	Centre of Excellence for Research on Atherosclerosis and Its Complications – Cardiac and Cerebral Infarction, ITMS: 26220120040 (2010-2013)
CEVA:	Center of Excellence for Atherosclerosis Research, ITMS: 26220120025 (2009-2011)
SEPO-II:	Building infrastructure in the center of excellence, ITMS: 26220120039 (2010-2013)
SEPO:	Network of centers of excellence for oncology, ITMS: 26220120024 (2009-2011)
FRAMEWORK PROJECT 5 QLRT-2000-00091:	Effect of PAHs in environmental pollution on exogenous and endogenous DNA damage (2000-2003)
INCO	Biomonitoring of occupationally exposed populations to acrylonitrile (1997-2000)
COPERNICUS	
IC15-CT97-0302:	Significance of biomarkers of exposure to complex mixtures of PAHs and nitro-PAHs (1995-1998)
COPERNICUS	
CIPA-CT94-0113:	Study of genetically determined susceptibility to lung tumors induced by environmental factors
KLV 44/97:	
VEGA 1/0863/15:	Interaction of genetic background and chronic intermittent hypoxia in the pathogenesis of cardiovascular complications of obstructive sleep apnea.
VEGA 1/1132/12:	Identification of biomarkers in relation to therapy effectiveness and prognosis in patients with follicular lymphoma
VEGA 1/0715/11:	Molecular genetic diagnostics in children with nephrotic syndrome
VEGA 1/0380/10:	Monitoring the impact of candidate gene polymorphisms for type 2 diabetes mellitus on the effectiveness of treatment with oral antidiabetic drugs from the sulfonylurea derivatives and dipeptidyl peptidase-4 (DPP-4) inhibitor groups
VEGA 1/4231/07:	The relationship between candidate gene polymorphisms and the risk, progression, and severity of chronic obstructive pulmonary disease – <i>Deputy principal investigator</i>
VEGA 1/4304/07:	Monitoring the effect of candidate gene polymorphisms on the age of onset of type 2 diabetes mellitus, levels of atherosclerosis risk factors, and the occurrence of macrovascular complications of diabetes
VEGA 1/2314/05:	Genetic aspects of selected forms of orthostatic intolerance

VEGA 1/2312/05:	Molecular biology of pulmonary hypertension and obstructive ventilatory disorder in patients with chronic obstructive pulmonary disease
VEGA 1/8297/01:	Factors contributing to the progression of renal diseases
VEGA 1/2297/95:	Study of the adaptive response of human cells to low doses of mutagens
IG-4 LF UPJŠ:	Molecular-biological detection, isolation, and immunophenotypic characterization of circulating tumor cells in correlation with histopathological findings in patients with urothelial carcinoma of the urinary bladder, and the application of results in clin
IG-4 LF UPJŠ:	The relationship between gene polymorphisms and pulmonary function in chronic obstructive pulmonary disease(2002-2004)
IG-4 LF UPJŠ:	Analysis of gene–environment interactions in diabetes and their contribution to atherosclerosis development in type 2 diabetes mellitus (2002-2004)
IG-3 LF UPJŠ:	Early diagnosis of progressive kidney diseases (2000-2002)
IG-3 LF UPJŠ:	The significance of p53 gene polymorphism in lung and bladder cancer (2000-2002)
IG-2 LF UPJŠ:	Study of genetic factors predisposing to the development of dementias (1999-2001)
IG-2 LF UPJŠ:	Effect of hypoglycemic and hypolipidemic treatment on PAI-1 concentrations in relation to genetic predisposition (1999-2001)
IG-1 LF UPJŠ:	Preimplantation genetic diagnosis (1998-2000)

Other international projects:

GSEC:	An International Pooled Data Analysis Project – GSEC – Genetic Susceptibility to Environmental Carcinogens (1999-2001) – <i>co-investigator</i>
-------	---

Bilateral mobility projects:

FBR-PDI-012	EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic “Genomic instability and cancer “GenICa”– <i>co-investigator</i>
-------------	--

RNDr. Martina Šemeláková, PhD.

Principal investigator:

VVGS-pf-2016 142:	Polymorphisms of the CYP3A4 gene
-------------------	----------------------------------

Co-investigator of projects:

KEGA 024UPJŠ-4/2024:	Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches ‘PraktikMed’ – <i>Deputy principal investigator</i>
----------------------	--

26110230088 SOFOS	Development of knowledge and skills of UPJŠ employees and students with an emphasis on interdisciplinary competencies and integration into international research centers
VEGA 1/0536/19:	The role of the erythropoietin receptor in the cellular response of breast adenocarcinoma to paclitaxel under in vitro and in vivo conditions
VEGA 1/0147/15:	Pleiotropic effects of non-activated or photodynamically active hypericin on factors influencing cancer cell resistance
VEGA 1/1025/12	Molecular biology versus morphology
VEGA 1/0477/10	Phylogeography of selected representatives of the genus <i>Erebia</i> (Lepidoptera, Nymphalidae) from the Carpathians.
VEGA 1/0240/08:	The effect of changes in (phospho)lipid composition of cell membranes on the proliferation and survival of colorectal tumor epithelial cells in an experimental model of cancer therapy
VEGA 1/3253/06:	Molecular-biological basis of the adverse effect of erythropoietin in cancer cell therapy
VEGA 1/9211/02:	Hypericin in photodynamic therapy: The role of unsaturated fatty acids and their metabolites in the proliferation, differentiation, and death of cancer cells
APVV-0321-07:	Hypericum spp. as a source of bioactive compounds with antitumor activity
APVT-20-012104:	Erythropoietin and its effect on tumor growth in vitro and in vivo
APVT-20-003704:	Hypericum perforatum L.: Genetic aspects of hypericin synthesis and its photocytotoxic effects
APVV-14-0154:	Transcriptome, metabolome, and signalome of bioactive compounds with antitumor effects in the genus <i>Hypericum</i>
MVTS (ČR/SR/SK-75/06):	Bil/ČR/SR/SK-75/06; The effect of phospholipid metabolism modulation on the proliferation and apoptosis of cancer cells in interaction with cytotoxic agents
VVGS /001/2004/B:	Slovak-Czech collaboration – Study of cell cycle changes depending on the conditions of hypericin-induced photodynamic therapy
VVGS 132/2006:	Does ceramide act as an apoptotic factor in the response of cancer cells to hypericin-induced photodynamic intervention?
QLRI-CT-2000-01455:	Projects of the 5th EU Framework Programme, European collection of rumen protozoa cultures (European rumen ciliate culture collection-ERCULE, QLRI-CT 2000 01455)
VVCE-0001-07:	Support for the establishment and operation of research and educational centers of excellence – APVV, Project title: Signal Research Center
COST Action: CA22119:	Haemoglobinopathies in European Liaison of Medicine and Science (HELIOS) 20/9/2023-19/9/2027

Bilateral mobility projects:

FBR-PDI-012	EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic “Genomic instability and cancer “GenICa”– <i>Principal investigator</i>
-------------	---

prof. RNDr. Janka Vašková, PhD.

Principal investigator:

VEGA 1/0559/18: Study of the onset and progression of periodontitis using advanced molecular and biochemical methods

Co-investigator of projects:

APVV-22-0357: Non-invasive diagnostics based on ncRNA
VEGA 1/0333/20: Tear fluid and saliva in preventive, predictive, and personalized medicine – *Deputy principal investigator*
VEGA 1/0782/15: The effect of humic acids and other natural substances on the functional state of selected organs and their mitochondria under physiological conditions and during intoxications – *Deputy principal investigator*
VEGA 1/1236/12: The effect of humic and polyene fatty acids on the production health of animals, antioxidant status, mitochondrial activity, lipid profile, and the absorption of certain heavy metals and pesticides from feed – *Deputy principal investigator*
VEGA 1/0799/09: The effect of omega-3 polyunsaturated fatty acids and humic acids on animal metabolism and health, lipid composition, and oxidative stability of animal products and foods derived from them in relation to health – *Deputy principal investigator*
SORO: Innovation and implementation of new forms of education at the FHPV PU in Prešov, ITMS: 26110230100 (2013-2015)
VEGA 1/0322/14: Indole phytoalexins – mechanism of antiproliferative action
VEGA 1/0999/11: The effect of polyphenols and monoamine oxidase inhibitors on mitochondrial function
VEGA 1/0456/11: Interaction of nutritional and genetic factors in the pathogenesis of metabolic syndrome development in the Roma and majority populations of the Eastern Slovak region
VEGA 1/0624/08: Study of the relationship between the structure and effect of chalcones on mitochondria
VEGA 1/0643/08: The effect of retinoids on neurotransmitter expression during different stages of postnatal development in rats

Bilateral mobility projects:

HO 596/2007: Investigation of interaction of cytotoxic and cytoprotective chalcones with DNA (Senior tutorial studies HSB-2008, one-month research stay)
ASO 06/07-14/2007: Study of interactions of selected natural and synthetic cyclic chalcone analogues with mitochondria – *co-investigator*
ASO 05/06-KE-001: Study of interactions of selected natural and synthetic cyclic chalcone analogues with mitochondria - *co-investigator*

RNDr. Jozef Židzik, PhD.

Principal investigator:

- VEGA 1/4231/07: The relationship of candidate gene polymorphisms to the risk, progression, and severity of chronic obstructive pulmonary disease
- VVGS 35/2006: The effect of candidate gene polymorphisms on the development, progression, and pharmacotherapy of chronic obstructive pulmonary disease (COPD)

Co-investigator of projects:

- KEGA 024UPJŠ-4/2024: Implementation of practical courses in biomedical research for doctoral students and Integration of researchers into new teaching approaches 'PraktikMed'
- VEGA 1/0050/24: Analysis of selected genetic variants associated with the efficacy of GLP-1 receptor agonists in lowering HbA1c and body weight in type 2 diabetes patients
- VEGA 1/0534/23: Targeted genetic screening in patients with Alport syndrome
- VEGA 1/0183/20: Monitoring genomic and proteomic markers of atherosclerosis progression in peripheral and carotid arteries in type 2 diabetes
- MZ SR-2019/29-UPJŠ-1: Monitoring the relationship between selected gene variants and proteomic markers in patients with mental disorders as a contribution to their personalized treatment
- VEGA 1/0724/15: Newly discovered genetic mutations in the etiopathogenesis of dystonias: their significance, prevalence, and manifestation
- VEGA 1/0389/14: Investigation of the relationship between variants of selected candidate genes for atherosclerosis and the severity of peripheral arterial occlusive disease of the lower limbs in patients with type 2 diabetes
- VEGA 1/0340/12: Monitoring the effect of gene polymorphisms influencing the pharmacokinetics and pharmacodynamics of metformin on the treatment response to metformin in patients with type 2 diabetes
- APVV-0134-11: The role of hypoxia in the activation of molecular pathways associated with increased cardiovascular risk in patients with sleep apnea and their modulation by treatment
- VEGA 1/0525/10: Disorders of folate metabolism in the pathogenesis of multiple malformations.
- VEGA 1/0380/10: Monitoring the impact of candidate gene polymorphisms for type 2 diabetes mellitus on the effectiveness of treatment with oral antidiabetic drugs from the sulfonylurea derivatives and dipeptidyl peptidase-4 (DPP-4) inhibitor groups
- SEPO: Network of centers of excellence for oncology, ITMS projektu : 26220120024 (2009-2011)
- VEGA 1/0368/10: Investigation of the impact of the genetic background of patients with chronic hepatitis C on the success of interferon therapy

- VEGA 1/4304/07: Investigation of the effect of candidate gene polymorphisms on the age of onset of type 2 diabetes mellitus, levels of atherosclerosis risk factors, and the occurrence of macrovascular complications of diabetes
- APVV-16-0158: Obesity, sleep apnea and obesity-hypoventilation syndrome: the impact of hypoxia on cardiovascular parameters in obesity-associated respiratory diseases and possibilities for therapeutic intervention
- RP EU, QLK4-CT-2000-00091: EXPAH – Effects of PAHs in environmental pollution on exogenous and endogenous DNA damage. (2001-2003)

Bilateral mobility projects:

- FBR-PDI-012 EEA and Norway grant: Bilateral relations and common knowledge between Slovakia and Iceland research at Universities on topic “Genomic instability and cancer “GenICa”– *co-investigator*